Linrodostat
Linrodostat is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target indoleamine 2,3-dioxygenase 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
25 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | — | — | 1 | 2 | 1 | — | — | 3 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 1 | 1 | — | — | 2 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | 1 | 1 | — | — | 2 |
| Head and neck neoplasms | D006258 | — | — | — | — | 1 | — | — | 1 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | — | 1 | — | — | 1 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 6 | 5 | — | — | — | 8 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | 1 | — | — | — | 1 |
| Endometrioid carcinoma | D018269 | — | — | — | 1 | — | — | — | 1 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | — | 1 | — | — | — | 1 |
| Squamous cell carcinoma | D002294 | — | — | — | 1 | — | — | — | 1 |
| Squamous cell neoplasms | D018307 | — | — | — | 1 | — | — | — | 1 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | 1 | — | — | — | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 5 | — | — | — | — | 5 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Linrodostat |
| INN | linrodostat |
| Description | Linrodostat (development code BMS-986205) is an experimental drug being studied for its immunomodulating and antineoplastic activities.
|
| Classification | Small molecule |
| Drug class | enzyme inhibitors: indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H](C(=O)Nc1ccc(Cl)cc1)C1CCC(c2ccnc3ccc(F)cc23)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 1923833-60-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297598 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB14986 |
| UNII ID | 0A7729F42K (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
IDO1
IDO1
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 389 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
74 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use